This article was originally published in The Gray Sheet
Magnetic resonance imaging device developer nets approximately $4.7 mil. from recently completed oversubscribed initial public offering. Underwritten by D.H. Blair, the offering involved the sale of 1 mil. units at $6 per share; each unit consisted of one share of Class A common stock, one redeemable Class A warrant and one redeemable Class B warrant. The Hicksville, New York-based firm filed a registration statement last December proposing an offering of 833,000 units ("The Gray Sheet" Jan. 18, I&W-3).
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.